Repligen Corp (NASDAQ:RGEN)
| CAPS Rating |
|
|---|---|
| Open | $4.23 |
| Previous Close | $4.22 |
| Daily Range | $4.20 - $4.25 |
| 52-Week Range | $2.90 - $4.99 |
| Market Cap | $129.72M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 12,089 |
| Average Daily Volume | 0 |
RGEN
VS S&P 500 (SPY)
How do you think RGEN will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
RGEN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
RGEN News and Commentary
- The Highest-Rated Biotech Stocks – The Motley Fool
- Repligen Receives Fast-Track Designation From FDA – SmartMoney
- Repligen Earnings Preview – The Motley Fool
- 6 Cash Rich Biotech Stocks With Catalysts – SeekingAlpha
- Repligen Shares Plunged: What You Need to Know – The Motley Fool
- Repligen: A Promising Biotech Play – SeekingAlpha
- Repligen's Promising Potential in 2011 – SeekingAlpha
- 5 Biotechs Investors Should Be Watching – SeekingAlpha
- GBMB Update – Blog at The Motley Fool
- UPDATE 1-FDA, EMA to re-analyze Repligen's late-stage data – Reuters
- Repligen Up On Orphan-Drug Status For Gene Defect Treatment – SmartMoney
- 4 Stocks That Laugh at Wall Street – The Motley Fool
- Sniffing around for more bottoms – Blog at The Motley Fool
- 5-Star Stocks Poised to Pop: Repligen – The Motley Fool
- UPDATE 1-Repligen pancreatic imaging agent does not meet goal – Reuters
- 7 Highly Rated Stocks on Sale – The Motley Fool
- Today's 5-Star Movers – The Motley Fool
- 7 Reasons Not to Worry This Week – The Motley Fool
- 5-Star Stocks on the Upswing – The Motley Fool
- 7 Stocks Einstein Would Love – The Motley Fool
RSS Headlines
Fool UK
